Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.55 |
| ▸ | SCN1A | P35498 | 1/20 | 0.55 |
| ▸ | SCN4A | P35499 | 1/20 | 0.55 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.55 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.55 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28394643 | 1.00 | SCN9A (0.60) | SCN9ASCN5ASCN1ASCN4ASCN7A | |
| SCHEMBL18013239 | 0.92 | SCN9A (0.64) | SCN9ASCN5ASCN7A | |
| SCHEMBL28383912 | 0.92 | SCN9A (0.64) | SCN9ASCN5ASCN7A | |
| SCHEMBL20668665 | 0.91 | SCN9A (0.57) | SCN9ASCN5ASCN4A | |
| SCHEMBL18013219 | 0.88 | SCN9A (0.61) | SCN9ASCN5ASCN1ASCN4ASCN7A | |
| SCHEMBL20668667 | 0.88 | HDAC8 (0.46) | SCN9ASCN5ASCN1ASCN4ASCN7A | |
| SCHEMBL20668666 | 0.86 | MRGPRX4 (0.48) | SCN9A | |
| SCHEMBL28383931 | 0.86 | SCN9A (0.59) | SCN9ASCN5ASCN1ASCN4ASCN7A | |
| SCHEMBL28383934 | 0.86 | SCN9A (0.59) | SCN9ASCN5ASCN1ASCN4ASCN7A | |
| SCHEMBL20668617 | 0.83 | SCN9A (0.60) | SCN9ASCN5ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207430-B | Heterocyclic substituted N-sulfonyl benzamide derivative, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-04-28 | — | — | CN | disclosed |